Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2401-2410 Newer>

The Motley Fool October 10, 2005 Stephen D. Simpson	Apria's One Selling Point The home health-care provider seems to really be in trouble as it shops itself to potential buyers. The possibility (probability?) of a sale does offer some protection here for aggressive investors.
The Motley Fool October 10, 2005 Stephen D. Simpson	The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios.
BusinessWeek October 17, 2005 Amy Barrett	Prescription For Upheaval How the Medicare drug program is tightening the screws on Big Pharma.
The Motley Fool October 7, 2005 Brian Gorman	Merck's Tricky Sell A vaccine for human papillomavirus clears scientific hurdles, but marketing could prove its biggest obstacle.
The Motley Fool October 7, 2005 Rich Smith	Hooper Holmes Condemns Itself The medical-testing services provider slashed earnings guidance by half. The only wonder today is that Hooper's stock hasn't fallen more than the current 1.5%.
The Motley Fool October 6, 2005 Stephen D. Simpson	CardioDynamics' Pulse Fading The products from this small-cap medical technology company work. It's simply not selling enough of them. Investors, take note.
Managed Care September 2005 Ed Silverman	No Easy Fit For Specialty Hospitals Insurers worry that specialty hospitals will ultimately increase costs at nearby community hospitals
Managed Care September 2005 John Carroll	Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques.
Managed Care September 2005	There's Now a Correct Method For Defining ROI in Disease Management Health care consultant Al Lewis, the godfather of disease management, talks about how the industry went wrong, and is now going right, in describing its own value to health plans, public employers, and the government.
Managed Care September 2005 Arthur Lazarus	Individual Wariness Needed To Spot Biased Drug Research Full and accurate disclosure of conflicts by researchers does not ensure the prevention of publication of articles that are misleading or otherwise biased. Impossible-to-enforce mandates won't work. Pharmacy directors and others must pose the right questions to the right people.
<Older 2401-2410 Newer> Return to current articles.